MRFRの分析によると、世界のディスレクシア治療市場は、予測期間中に7.10％の注目すべきCAGRで大幅な市場拡大を遂げ、2027年末までに385億1467万ドルを超えると予測されています。調査によると、ディスレクシアは大脳がデータを処理する方法が原因で発生することがわかっています。ディスレクシアの人は、ハンディキャップを回避する方法を頻繁に求めるため、問題が発生していることに誰も気付きません。大多数は子供として分析されており、若者や大人でも起こり得ることはまだ想定されていません。
世界のディスレクシア治療市場は、2020年に最大の市場価値236億8,269万ドルに達したことから、市場は堅調に拡大すると予想されます。世界的なディスレクシア治療市場の推進要因は、ディスレクシアの症例数の増加と、とりわけディスレクシアを治療するためのアプリケーション改善エクササイズの拡大です。その副作用、および過小診断がディスレクシア治療市場の阻害要因です。そして学校、大学、および非利益団体との協調的な取組みが、世界的な失読症治療市場に参入しているプレーヤーにやりがいのあるオープンドアを与えます。
目次
TABLE OF CONTENTS
1 EXECUTIVE SUMMARY
2 MARKET INTRODUCTION
2.1 DEFINITION
2.2 SCOPE OF THE STUDY
2.3 RESEARCH OBJECTIVE
2.4 MARKET STRUCTURE
2.5 ASSUMPTIONS & LIMITATIONS
3 RESEARCH METHODOLOGY
3.1 DATA MINING
3.2 SECONDARY RESEARCH
3.3 PRIMARY RESEARCH
3.4 BREAKDOWN OF PRIMARY RESPONDENTS
3.5 FORECASTING TECHNIQUES
3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION
3.6.1 BOTTOM-UP APPROACH
3.6.2 TOP-DOWN APPROACH
3.7 DATA TRIANGULATION
3.8 VALIDATION
4 MARKET DYNAMICS
4.1 OVERVIEW
4.2 DRIVERS
4.2.1 INCREASING PREVALENCE OF DYSLEXIA
4.2.2 INCREASING APP DEVELOPMENT ACTIVITIES TO TREAT DYSLEXIA
4.2.3 GROWING NUMBER OF VITUAL REALITY-BASED EDUCATIONAL SOFTWARE
4.3 RESTRAINT
4.3.1 LACK OF AWARENESS ABOUT DYSLEXIA, ITS SYMPTOMS AND UNDERDIAGNOSIS
4.4 OPPORTUNITY
4.4.1 COLLABORATION WITH SCHOOLS, COLLEGES AND NON PROFIT ORGANIZATIONS
5 MARKET FACTOR ANALYSIS
5.1 VALUE CHAIN ANALYSIS
5.1.1 RESEARCH & DEVELOPMENT
5.1.2 MANUFACTURING
5.1.3 DISTRIBUTION
5.1.4 MARKETING & SALES
5.1.5 POST-SALES MONITORING
5.1.6 INPUTS
5.1.7 SOFTWARE DEVELOPMENT PROCESSES
5.1.8 OUTPUT
5.1.9 MARKETING AND DISTRIBUTION
5.1.10 POST-SELLING SERVICES
5.2 PORTER'S FIVE FORCES MODEL
5.2.1 BARGAINING POWER OF BUYERS
5.2.2 BARGAINING POWER OF SUPPLIERS
5.2.3 THREAT OF NEW ENTRANTS
5.2.4 THREAT OF SUBSTITUTES
5.2.5 INTENSITY OF RIVALRY
5.3 IMPACT OF COVID-19
5.4 DYSLEXIA DIAGNOSIS
5.5 DYSLEXIA TREATMENT
5.6 STANDARD PAPER TESTS VS ELECTRONIC VERSIONS
5.6.1 TESTS FOR DYSLEXIA AND LEARNING DISABILITIES (PRE-SCHOOLERS)
6 GLOBAL DYSLEXIA TREATMENT & DIAGNOSIS MARKET BY TYPE
6.1 OVERVIEW
6.2 PHONOLOGICAL DYSLEXIA
6.3 SURFACE DYSLEXIA
6.4 OTHERS
7 GLOBAL DYSLEXIA TREATMENT & DIAGNOSIS MARKET BY TREATMENT & DIAGNOSIS
7.1 OVERVIEW
7.2 TREATMENT
7.2.1 MEDICATIONS
7.2.1.1 ANTIHISTAMINES
7.2.1.2 CENTRAL NERVOUS STIMULANT
7.2.1.3 ANTI-MYOCLONIC
7.2.1.4 ATTENTION-DEFICIT HYPERACTIVITY DISORDER (ADHD) DRUG
7.2.1.5 OTHERS
7.2.2 TOOLS
7.2.2.1 E-READERS AND TABLETS
7.2.2.2 APPS
7.2.2.3 SMARTPENS
7.2.2.4 OTHERS
7.3 DIAGNOSIS
7.3.1 PAPER-BASED
7.3.2 DIGITAL-BASED
8 GLOBAL DYSLEXIA TREATMENT & DIAGNOSIS MARKET BY END USER
8.1 OVERVIEW
8.2 SPECIALTY CENTER
8.3 HOME CARE
8.4 HOSPITALS & CLINICS
8.5 OTHERS
9 GLOBAL DYSLEXIA TREATMENT & DIAGNOSIS MARKET, BY REGION
9.1 OVERVIEW
9.2 NORTH AMERICA
9.2.1 US
9.2.2 CANADA
9.3 EUROPE
9.3.1 GERMANY
9.3.2 UK
9.3.3 FRANCE
9.3.4 ITALY
9.3.5 SPAIN
9.3.6 REST OF EUROPE
9.4 ASIA PACIFIC
9.4.1 CHINA
9.4.2 JAPAN
9.4.3 INDIA
9.4.4 AUSTRALIA
9.4.5 SOUTH KOREA
9.4.6 REST OF ASIA-PACIFIC
9.5 REST OF THE WORLD
9.5.1 LATIN AMERICA
9.5.2 MIDDLE EAST
9.5.3 AFRICA
10 COMPETITIVE LANDSCAPE
10.1 COMPETITIVE OVERVIEW
10.2 MAJOR PLAYERS IN THE GLOBAL DYSLEXIA TREATMENT MARKET
10.3 MAJOR GROWTH STRATEGIES IN THE GLOBAL DYSLEXIA TREATMENT MARKET
10.4 COMPETITIVE BENCHMARKING
10.5 LEADING PLAYERS IN TERMS OF NUMBER OF DEVELOPMENTS IN THE GLOBAL DYSLEXIA TREATMENT MARKET
10.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
10.6.1 NEW PRODUCT DEVELOPMENTS/LAUNCHES
10.6.2 COLLABORATIONS/EXPANSIONS/PARTNERSHIPS/INVESTMENTS
10.7 MAJOR PLAYERS FINANCIAL MATRIX
10.7.1 REVENUE OF MAJOR PLAYERS, 2020
10.7.2 R&D EXPENDITURE, 2020
11 COMPANY PROFILES
11.1 PFIZER INC.
11.1.1 COMPANY OVERVIEW
11.1.2 FINANCIAL OVERVIEW
11.1.3 PRODUCTS OFFERED
11.1.4 KEY DEVELOPMENTS
11.1.5 SWOT ANALYSIS
11.1.6 KEY STRATEGIES
11.2 SPEECHIFY INC.
11.2.1 COMPANY OVERVIEW
11.2.2 FINANCIAL OVERVIEW
11.2.3 PRODUCTS OFFERED
11.2.4 KEY DEVELOPMENTS.
11.2.5 KEY STRATEGIES
11.3 JUBILANT PHARMA LIMITED
11.3.1 COMPANY OVERVIEW
11.3.2 FINANCIAL OVERVIEW
11.3.3 PRODUCTS/SERVICES OFFERED
11.3.4 KEY DEVELOPMENTS
11.3.5 KEY STRATEGIES
11.4 LINGIT AS
11.4.1 COMPANY OVERVIEW
11.4.2 FINANCIAL OVERVIEW
11.4.3 PRODUCTS OFFERED
11.4.4 KEY DEVELOPMENTS
11.4.5 KEY STRATEGIES
11.5 SOLI
11.5.1 COMPANY OVERVIEW
11.5.2 FINANCIAL OVERVIEW
11.5.3 PRODUCTS OFFERED
11.5.4 KEY DEVELOPMENTS
11.5.5 KEY STRATEGIES
11.6 NOVARTIS AG
11.6.1 COMPANY OVERVIEW
11.6.2 FINANCIAL OVERVIEW
11.6.3 PRODUCTS/SERVICES OFFERED
11.6.4 KEY DEVELOPMENTS
11.6.5 SWOT ANALYSIS
11.6.6 KEY STRATEGIES
11.7 LYFTA
11.7.1 COMPANY OVERVIEW
11.7.2 FINANCIAL OVERVIEW
11.7.3 PRODUCTS/SERVICES OFFERED
11.7.4 KEY DEVELOPMENTS
11.7.5 KEY STRATEGIES
11.8 GLAXOSMITHKLINE
11.8.1 COMPANY OVERVIEW
11.8.2 FINANCIAL OVERVIEW
11.8.3 PRODUCTS OFFERED
11.8.4 KEY DEVELOPMENTS
11.8.5 SWOT ANALYSIS
11.8.6 KEY STRATEGIES
11.9 TEVA PHARMACEUTICAL INDUSTRIES LTD.
11.9.1 COMPANY OVERVIEW
11.9.2 FINANCIAL OVERVIEW
11.9.3 PRODUCTS/SERVICES OFFERED
11.9.4 KEY DEVELOPMENTS
11.9.5 SWOT ANALYSIS
11.9.6 KEY STRATEGIES
11.10 ELI LILLY & COMPANY
11.10.1 COMPANY OVERVIEW
11.10.2 FINANCIAL OVERVIEW
11.10.3 PRODUCTS/SERVICES OFFERED
11.10.4 KEY DEVELOPMENTS
11.10.5 SWOT ANALYSIS
11.10.6 KEY STRATEGIES
11.11 RPG LIFE SCIENCES LTD
11.11.1 COMPANY OVERVIEW
11.11.2 FINANCIAL OVERVIEW
11.11.3 PRODUCTS/SERVICES OFFERED
11.11.4 KEY DEVELOPMENTS
11.11.5 KEY STRATEGIES
11.12 HOPALAI D.O.O.
11.12.1 COMPANY OVERVIEW
11.12.2 FINANCIAL OVERVIEW
11.12.3 PRODUCTS/SERVICES OFFERED
11.12.4 KEY DEVELOPMENTS
11.12.5 KEY STRATEGIES
12 APPENDIX
12.1 REFERENCES
12.2 RELATED REPORTS
